MedPath

Effect of supplement containing dihydroquercetin on Insulin Resistance in Obesity -A randomized, double-blind, and parallel group study

Not Applicable
Conditions
Healty volunteer
Registration Number
JPRN-UMIN000018418
Lead Sponsor
KSO Corporation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1)Subjects who use oral medication affecting blood glucose. 2)Subjects who constantly use supplements and/or functional foods (including Food for Specified Health Uses, Food with function claims) affecting blood glucose. 3)Subjects who have declared allergic reaction to ingredients contained in test diets. 4) Subjects who are diabetes (including those who are treated with insulin administration) 5)Subjects who contract or are under treatment or are medical history for serious diseases (e.g.,liver disease, kidney disease, and/or heart disease), thyroid gland disease, adrenal gland disease, and/or metabolic disorder. 6)Subjects who have a chronic disease and use medicines continuously. 7)Subjects who have a history of digestive disease affecting digestion and absorption. 8) Subjects whose fasting blood glucose are above 140 mg/dl. 9)Subjects who are judged as unsuitable for the study based on the results of blood tests by the investigator. 10)Subjects who have donated over 200 mL of blood and/or blood components within the last one month prior to the current study or over 400 mL of blood and/or blood components within the last three months prior to the current study. 11)Subjects who are diagnosed as anemic and not suitable for frequent collection of blood. 12)Subjects who are under treatment for or have a history of drug addiction and/or alcoholism. 13)Subjects who are planning to participate in other clinical studies. 14)Subjects who are judged as unsuitable for the study by the investigator for other reasons.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ISI(Matsuda Index)
Secondary Outcome Measures
NameTimeMethod
HOMA-R, HOMA-beta, glucose, insulin, AUC of glucose and insulin, QUICKI
© Copyright 2025. All Rights Reserved by MedPath